Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of XELOX Regimen Combined With GLS-010 and Lenvatinib in Patients With Advanced AFP-positive Gastric Cancer: a Single Center, Prospective, Open Label Phase I Study

NCT05221775 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05221775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05221775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of XELOX Regimen Combined With GLS-010 and Lenvatinib in Patients With Advanced AFP-positive Gastric Cancer: a Single Center, Prospective, Open Label Phase I Study
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 1, 2021
Completion date
October 1, 2023
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric carcinoma, first-line treatment